Асосий контентга ўтиш
AkademIndex

Маҳсулотлар

Ишлаб чиқувчилар учун

AkademBaseЭкотизим учун очиқ API

Khasan Safaev

9 та иш

RSSPMCPh&P, Ministry of Health of the Republic of Uzbekistan, Tashkent, Uzbekistan

  1. Person-centred care in practice: perspectives from a short course regimen for multi-drug resistant tuberculosis in Karakalpakstan, Uzbekistan

    Shona Horter, Beverley Stringer, Nell Gray +5

    МақолаTuberculosis Research and EpidemiologyBMC Infectious Diseases20203 иқтибос
    ABI

  2. Trends, Characteristics and Treatment Outcomes of Patients with Drug-Resistant Tuberculosis in Uzbekistan: 2013–2018

    Khasan Safaev, Nargiza Parpieva, Irina Liverko +5

    МақолаTuberculosis Research and EpidemiologyInternational Journal of Environmental Research and Public Health20212 иқтибос
    ABI

  3. Scaling Up Molecular Diagnostic Tests for Drug-Resistant Tuberculosis in Uzbekistan from 2012–2019: Are We on the Right Track?

    Sharofiddin Yuldashev, Nargiza Parpieva, Salikhdjan Alimov +6

    МақолаTuberculosis Research and EpidemiologyInternational Journal of Environmental Research and Public Health20212 иқтибос
    ABI

  4. Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan

    Philipp du Cros, Atadjan Khamraev, Zinaida Tigay +15

    МақолаTuberculosis Research and EpidemiologyERJ Open Research20201 иқтибос
    ABI

  5. Mutations in the genes of drug-resistant mycobacterium tuberculosis in Uzbekistan

    Nargiza Parpieva, Vera Beloserkoves, Khasan Safaev +1

    МақолаTuberculosis Research and EpidemiologyEuropean Respiratory Journal20140 иқтибос
    ABI

  6. Second-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan

    S. Moe, I. Azamat, Sholpan Allamuratova +14

    МақолаTuberculosis Research and EpidemiologyIJTLD OPEN20240 иқтибос
    ABI

  7. The effectiveness of pulmonary tuberculosis treatment during the COVID-19 pandemic

    Ruzilya Usmanova, Nargiza Parpieva, Irina Liverko +6

    МақолаCOVID-19 Prevention and Impact20240 иқтибос
    ABI

  8. A 10-year review of isoniazid-resistant TB management in Uzbekistan 2009-2020

    Michael L. Rekart, Phone Thit, Modupe Oluya +14

    Шарҳ мақолаTuberculosis Research and EpidemiologyIJTLD OPEN20240 иқтибос
    ABI

  9. The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)–Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings—A Prospective Cohort Study in Belarus and Uzbekistan

    Animesh A. Sinha, Robert J. Klebe, Michael L. Rekart +22

    МақолаTuberculosis Research and EpidemiologyClinical Infectious Diseases20250 иқтибос
    ABI